Abstract
LKB1 (also known as serine-threonine kinase 11, STK11) is a tumor suppressor, which is mutated or deleted in Peutz-Jeghers syndrome (PJS) and in a variety of cancers. Physiologically, LKB1 possesses multiple cellular functions in the regulation of cell bioenergetics metabolism, cell cycle arrest, embryo development, cell polarity, and apoptosis. New studies demonstrated that LKB1 may also play a role in the maintenance of function and dynamics of hematopoietic stem cells. Over the past years, personalized therapy targeting specific genetic aberrations has attracted intense interests. Within this review, several agents with potential activity against aberrant LKB1 signaling have been discussed. Potential strategies and challenges in targeting LKB1 inactivation are also considered.
Keywords: LKB1 (serine-threonine kinase 11, STK11), AMP-activated protein kinase (AMPK), tumor suppression, mutations, targeting therapeutics.
Current Drug Targets
Title:Targeting the LKB1 Tumor Suppressor
Volume: 15 Issue: 1
Author(s): Rui-Xun Zhao and Zhi-Xiang Xu
Affiliation:
Keywords: LKB1 (serine-threonine kinase 11, STK11), AMP-activated protein kinase (AMPK), tumor suppression, mutations, targeting therapeutics.
Abstract: LKB1 (also known as serine-threonine kinase 11, STK11) is a tumor suppressor, which is mutated or deleted in Peutz-Jeghers syndrome (PJS) and in a variety of cancers. Physiologically, LKB1 possesses multiple cellular functions in the regulation of cell bioenergetics metabolism, cell cycle arrest, embryo development, cell polarity, and apoptosis. New studies demonstrated that LKB1 may also play a role in the maintenance of function and dynamics of hematopoietic stem cells. Over the past years, personalized therapy targeting specific genetic aberrations has attracted intense interests. Within this review, several agents with potential activity against aberrant LKB1 signaling have been discussed. Potential strategies and challenges in targeting LKB1 inactivation are also considered.
Export Options
About this article
Cite this article as:
Zhao Rui-Xun and Xu Zhi-Xiang, Targeting the LKB1 Tumor Suppressor, Current Drug Targets 2014; 15 (1) . https://dx.doi.org/10.2174/1389450114666140106095811
DOI https://dx.doi.org/10.2174/1389450114666140106095811 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Why are People with “Poor Lung Function” At Increased Atherothrombotic Risk?A Critical Review with Potential Therapeutic Indications
Current Vascular Pharmacology A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease
Current Pharmaceutical Design Chemoenzymatic Pathways towards Novel Peptide Antibiotics
Anti-Infective Agents in Medicinal Chemistry Aging of the Innate Immune System: An Update
Current Immunology Reviews (Discontinued) Sleep and the Immune System
Current Immunology Reviews (Discontinued) Nucleosides, a Valuable Chemical Marker for Quality Control in Traditional Chinese Medicine Cordyceps
Recent Patents on Biotechnology Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews Endocannabinoid Receptor Antagonists and Other Emerging Pharmacological Strategies for Weight Reduction
Current Drug Targets - Cardiovascular & Hematological Disorders Evaluation of Antioxidant, Antityrosinase Activities and Cytotoxic Effects of Phyllanthus amarus Extracts
The Natural Products Journal A Transporter Gene (Sodium Iodide Symporter) for Dual Purposes in Gene Therapy: Imaging and Therapy
Current Gene Therapy Treatment Options for Cystic Fibrosis: State of the Art and Future Perspectives
Reviews on Recent Clinical Trials Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets DMBA- Induced Breast Cancer: A Hormonal Camouflage
Current Cancer Therapy Reviews Viral Latent Proteins as Targets for Kaposis Sarcoma and Kaposis Sarcoma-associated Herpesvirus (KSHV / HHV-8) Induced Lymphoma
Current Drug Targets - Infectious Disorders Therapeutic Potential of the Mammalian Pyruvate Dehydrogenase Kinases in the Prevention of Hyperglycaemia
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Immunometabolism in Health and Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacology and Perioperative Considerations for Diabetes Mellitus Medications
Current Clinical Pharmacology Current State of ERG as Biomarker in Prostatic Adenocarcinoma
Current Cancer Drug Targets Preface [Hot topic: Autoimmunity (Executive Editors: D. Stahl and W. Sibrowski)]
Current Pharmaceutical Design What Fans the Fire: Insights into Mechanisms of Leptin in Metabolic Syndrome- Associated Heart Diseases
Current Pharmaceutical Design